Cost-effectiveness analysis of current non-mandatory hepatitis B vaccination coverage vs expanding coverage among healthcare workers in Ethiopia

Dinksew Tewuhibo¹, Getahun Asmamaw²* and Wondim Ayenew³

Abstract

Background: Ethiopia is a country with high endemicity in Hepatitis B (HepB) virus infection. However, only 14% of healthcare workers (HCWs) are currently immunized via a non-mandatory strategy in the country. Hence, this study aimed to estimate the cost-effectiveness of the current vaccination coverage and increasing coverage among HCWs in Ethiopia.

Methods: Based on current practice, the study considered a monovalent HepB vaccine, which has a 90% protection rate with a complete three-dose series for lifelong protection. Markov model for current coverage (14%) and expanding vaccination coverage to 80% (as per World Health Organization (WHO) recommendation) was simulated based on the data got from both primary and secondary data. Secondary data, particularly cost and effectiveness data, were gained from published articles, WHO guidelines, and Ethiopian Federal Ministry of Health documents. Cost-related data for vaccination and chronic HepB treatment were also gathered by interviewing expertise from Tikur Anbesa specialized hospital. We conducted the study from a healthcare payer perspective, with a 3% discount rate of cost and health outcome as recommended by the WHO. The primary health outcome was measured by the Incremental Cost-Effectiveness Ratio (ICER). We employed deterministic analysis and tornado diagrams to manage parameter uncertainty and show a plausible range of cost and effectiveness of variables.

Results: Current vaccination program is more expensive (USD 29.99) with a more additional cost of USD 1.32 and with reduced effectiveness of 0.08 Life Years (LYs) compared to the expanded HepB vaccination strategy which costs USD 28.67 and gives a relatively high total LY gain of 28.62. The resulting ICER was USD-16.23 per LYs gained. The negative ICER shows that the expanded HepB vaccination strategy dominated the current vaccination strategy. A one-way sensitivity analysis also revealed that the current vaccine coverage was dominated by an increase in the risk of infection among unvaccinated individuals.

Conclusions: Expanded vaccination coverage (to 80%) was found the most cost-effective strategy in Ethiopian HCWs compared to the current non-mandatory vaccine coverage (14%). In addition, the results of one-way and two-way sensitivity analysis reveal the robustness of our model conclusion.
Keywords: Cost-effectiveness, Hepatitis-B virus prevalence, Hepatitis-B vaccination coverage, Healthcare workforce, Ethiopia

Background

Hepatitis B Virus (HBV) is one of the serious global health burdens that affects the lives of over two billion people [1, 2]. It is primarily transmitted through percutaneous or mucosal contact with infected blood and body fluids, and through occupational exposure of healthcare workers (HCWs) during dental, medical, and surgical procedures [1]. HBV could be acute or chronic based on the persistence of Hepatitis B (HepB) surface antigen (HBsAg) for less or over 6 months [3]. Most of acute HepB infections are self-limiting and do not require treatment. However, 0.5–1% of people could develop fulminant hepatitis, which has a mortality rate of 70–80% [4]. Meanwhile, 3–5% of adults with acute HepB have a chance of progressing into Chronic Hepatitis B (CHB) [5]. Patients with CHB have a 40% risk of developing sequelae such as cirrhosis, liver failure, and Hepatocellular Carcinoma [3]. Thus, 5–25% of people with CHB infection die each year because of liver complications [6]. Despite this, only 5% of CHB patients have access to treatment in Ethiopia for a variety of reasons, including a lack of finance, a scarcity of molecular diagnostic tests, regulatory limits on antiviral medications, and a lack of commitment from policymakers [6, 7].

WHO recently estimated that over 350 million people globally are chronic carriers of the virus [8]. The endemicity of HBV varies across the globe, with Asia and Africa having the highest prevalence [9]. HCWs, in particular, are ten times more likely than the general population to acquire HBV [10]. The annual global incidence of HepB infection in HCWs is approximately 6% [8, 11]. Similarly, a high risk of exposure was reported among physicians, clinical nurses, midwives, laboratory technicians, and anesthetists in Ethiopia [12, 13]. Existing evidence also supports the high prevalence of HepB among HCWs in Ethiopia [14]. For example, at Gondar and Addis Ababa referral hospitals, the seroprevalence of HepB viral infection was 4.52% and 2.6%, respectively [12, 13]. Predisposing factors such as contamination because of medical procedures and work overload are majorly claimed to be responsible [13, 15–17]. This implies that the burden of this viral infection is an additional challenge for Ethiopia's healthcare system, which has been facing infectious and non-communicable diseases [14].

Three doses of monovalent HepB vaccinations given every 6 months are currently the most effective and safe strategy to prevent HepB infection [18]. WHO and the Ethiopian Federal Ministry of Health (FMOH) both encourage that all HCWs be vaccinated against HBV [5, 14]. These institutions have aimed to achieve HBV vaccine coverage of at least 80% among HCWs [19, 20]. However, HBV vaccine coverage among the entire healthcare workforce who directly or indirectly participate in healthcare service delivery, including health extension workers, medical waste handlers, and janitors, has remained low in several countries (<20%) [21]. Similarly, the minimal (14%) coverage of HepB vaccination among healthcare professionals was also reported in Ethiopia [13, 17]. Unfortunately, a non-mandatory strategy is being used for vaccination against HBV in HCWs in the country [13, 17]. Hence, this cost-effectiveness analysis determined the cost averted and disease prevention (life year gains) of increasing HepB vaccine coverage among all healthcare workforces such as nurses, laboratory, pharmacy, medical doctors, midwives, janitors, supportive staff compared to current non-mandatory HepB vaccination coverage (14%).

Methods

Study population and design

Ethiopian FMOH is the primary public healthcare provider, in charge of policy formation, planning, development, and management of all health issues. The minister’s office employs around 241,250 people in the health sector, including health extension workers (15%), paramedical professionals (35%), medical doctor professionals (3%), supportive and administrative personnel (30%), and others [20]. In this report, the average age of HCWs is 32 years, which was considered in the analysis. This study included all Ethiopian HCWs because of their higher occupational exposure to HBV than the general population [12]. All healthcare facilities in the country, including 16,243 health posts, 3,743 health centers, 220 primary hospitals, 64 general hospitals, 27 referral hospitals, and other administrative offices such as the regional health bureau, district health offices, and FMOH were also considered [20]. The study was conducted from the healthcare payer perspective (Ethiopian FMOH) (Table 1). Furthermore, since it was assumed that vaccines offer lifetime protection, the cost of expanding vaccination coverage, impact on LY gains, and ICER were assessed over the 65-year lifetime of HCWs. Therefore, the cost and LYs were adjusted to a 3% discount rate as of WHO recommendation (Table 1). Accordingly, a synthesis-based estimate of the data was used, references to many studies from China, the USA, and Ethiopia were...
made, and a mean value was taken to correct misleading data findings from a single study [1, 5, 8, 15, 22].

All necessary pharmaceuticals, including the HepB vaccine, were procured and supplied primarily by the Ethiopian Pharmaceutical Supply Agency (EPSA). EPSA is an institution in providing pharmaceuticals, laboratory reagents, medical equipment, and supplies to the Ethiopian people (direct supplier to healthcare facilities in the country) [23]. Antivirals such as Tenofovir 300 mg and Lamivudine 150 mg which are used to treat of CHB are not included in the pharmaceutical procurement list of Ethiopia [24]. However, they are assumed to be supplied by EPSA and are currently available at Tikur Anbesa specialized Hospital (TASH); the largest referral hospital in the country. Cost-related data were gathered by interviewing experts from TASH (Nurses, physicians, and Pharmacists), and WHO HBV guidelines. Effectiveness-related information was also gathered from distinctive pieces of literature review. All costs were expressed in United States dollars (USD) at an exchange rate of 28 Ethiopian Birr to USD 1 on June 11, 2019.

Model structure
The model began with a mean age of average Ethiopian HCWs (32 years) and included 33 cycles (1-year cycle length) to simulate the disease process over the worker’s lifetime (65 years as an average Ethiopian life expectancy). The model of HBV disease progress depicted in Fig. 1 indicates any susceptible individual may stay in a “susceptible state” without acquiring an infection. Otherwise, get infected by HBV first acutely with a 5–10% chance of progressing to CHB and a 0.5–1% case fatality rate. The other chance for susceptible individuals is to develop self-immunity or get vaccinated for prior infection. Any person who has immunity could stay in an “immune” health state. The other health state is the “Chronic hepatitis” state. In this health state, an infected person may live as a chronic carrier or get treatment and then progress to a healthy (“immune”) state. When any abnormality follows or results from a CHB infection

| Disease     | Hepatitis B     |
|-------------|-----------------|
| Population  | Healthcare workforce |
| Intervention| Increasing vaccination |
| Comparators | Current vaccination |
| Outcome     | Disease prevented, QALY gained, Cost |
| Perspective | Healthcare payer |
| Time Horizon| Lifetime |
| Discounting | 3% |
| Sensitivity Analysis | Deterministic Sensitivity analysis |
| Type of Model | Markov modeling |

**Table 1** Method summary of economic evaluations of cost-effectiveness analysis of expanding hepatitis B vaccination among the healthcare workforce in Ethiopia

**Fig. 1** Model of hepatitis B virus disease progress and consequence
such as liver permanent damage (cirrhosis, Ascites, and hepatocellular carcinoma), the individual enters into “Sequelae” health state. Despite this, any health state has a probability of entering an absorbing state (death).

Assumptions
Hepatitis B vaccines are available in different formulations for an instant in combination with other vaccines, such as diphtheria–tetanus–pertussis (DTP), Haemophilus influenza type b (Hib), and Inactivated Poliovirus (IPV). However, in this economic evaluation, only the monovalent HepB vaccine was considered, since it is presently implemented, with an effectiveness/protection rate of 90% in Ethiopia [8, 20]. The term ‘immunized’ was considered for HCWs receiving a complete series of 3 doses of HepB vaccine within a 6-month duration. All HCWs who did not receive the vaccination before were assumed to be eligible for vaccination without being screened for HBV. Our model did not account for the spread of HBV among HCWs or between healthcare facilities because of the lack of country-specific data. Because acute hepatitis is essentially a self-limiting infection, the cost of treatment is not considered in this economic evaluation. Only supportive care, such as resuscitation and symptomatic treatment, was considered for patients with liver complications, such as hepatocellular carcinoma and cirrhosis. In this study, it was assumed that vaccination results in the lifelong immunization of HCWs (up to 65 years).

Table 2 Various probability estimations of hepatitis B disease progression obtained from published follow-up studies

| Health event incidence/transition | Probability | Range       | Data source |
|----------------------------------|-------------|-------------|-------------|
| Incidence of hepatitis B infection without vaccination among HCWs | 0.6         | 0.4–0.8     | [15]         |
| The transition from acute hepatitis B to chronic HepB | 0.05       | 0.05–0.1   | [5]          |
| Progression of untreated HepB to sequelae (cirrhosis, HCC) | 0.05       | 0.02–0.054 | [1]          |
| Death due to HepB infection | 0.0106     | 0–0.0106   |             |
| Incidence of sequelae chronic following HepB treatment | 0.0175 | 0.017–0.022 | [5, 8] |
| Death due to HepB complication | 0.2         | 0.15–0.25   |             |

HCC hepatocellular carcinoma, HCWs Healthcare workers, HepB hepatitis B

Table 3 Estimated individual annual hepatitis B vaccination cost and hepatitis B disease management cost

| Service                     | List of items consumed/services provided | Total cost per year/cycle length |
|-----------------------------|-----------------------------------------|---------------------------------|
| Vaccination                 | Hepatitis B, glove, syringe              | USD 57                          |
| Hepatitis B treatment       | TDF 300 mg daily± diuretics              | USD 57                          |
| Laboratory investigation    | HBsAg ALT, AST, INR, BUN, Albumin, Creatinine | USD 88.56                      |
| Hospitalization cost        | Symptomatic treatment and bed admission  | USD 189                         |

ALT alanine amino transferase, AST aspartate amino transferase, HBsAg hepatitis B surface antigen, INR international normalized ratio, TDF tenofovir
sequelae such as cirrhosis, ascites, portal hypertension, and hepatocellular carcinoma were also added to the cost of laboratory tests and treatment. Liver transplant cost for patients with liver failure was not estimated, since it is not applicable in Ethiopia.

Most of the information regarding the cost of HepB vaccination and CHB disease management was obtained from pharmacists, nurses, and physicians who actively work in TASH at the department of Gastroenterology, pharmacy, and internal medicine. Indirect costs, transportation costs, capital item costs (such as cold chain storage, deep freezer vans, or vehicles), and other operational costs related to logistics were not included. Finally, the upfront cost (such as fryers/advertisement) to increase vaccine coverage was not considered due to a lack of data. The cost of the three series of vaccine doses and their administration costs (onetime costs) were considered at the beginning cycle of the simulation. Whereas the other costs (such as treatment, laboratory tests, and hospitalization costs) were considered over the lifetime of the healthcare workforce (Table 3).

Results

The expanded 80% coverage strategy was found to have higher total life year gains (28.62 LYs) with a lower investment of USD 28.67 compared to the current non-mandatory vaccination coverage (14%) program which is more expensive (USD 29.99) and has lower total life years (28.54 LYs). The expanded coverage averts the cost of USD 1.32 with the negative ICER value (USD-16.5 per LYs gain) (Table 4). This shows that expanding the vaccination program saves USD 16 compared to the current non-mandatory vaccination strategy, confirming its dominance and greater health benefits. The final average or expected costs of the two alternatives were less than the estimated costs which could be determined by the probability of getting the treatments such as Tenofovir or other treatments (due to unavailability and/or unaffordability issues). In general, increasing vaccination coverage to 80% dominated the current coverage through the non-mandatory vaccination strategy (Fig. 2).

One-way sensitivity analysis provides that the current vaccine coverage was still dominated by an increase in the risk of infection among unvaccinated individuals. For instance, the result of the ICER increased from $-0.9$ to $-0.81$ when the risk of infection among unvaccinated is increased. Accordingly, the cost has increased from USD 1.54–2.04, while the effectiveness had decreased from $-0.09$ to $-0.13$ as the chance of infection is raised with the current vaccine coverage. The additional cost incurred was due to post-infection treatment costs. Similarly, the tornado results revealed that the main parameters that may have an impact on the ICER value are the probability of death from sequelae, death from HepB infection, progression of untreated CHB to sequelae, cost of lab investigation, and probability of treating CHB (Fig. 3). The ICER value was increased by changing the cost parameters within the acceptable range and becomes decreased or increased with the varying probabilities of death due to sequelae and death due to HBV infection.

According to the two-way sensitivity analysis, increasing vaccination coverage enhances total LYs gain irrespective of the probability that CHB will result in death or the likelihood of HBV infection in unvaccinated individuals. Figure 4 shows that the current coverage strategy (blue) is dominated or covered by the expanded coverage one

| Table 4 | Base-case results from cost-effectiveness analysis of expanding HepB vaccination coverage vs current coverage (June 2019) |
|---------|----------------------------------------------------------------------------------|
| Strategy | Life Years | Cost   | Incremental LYs | Incremental cost | ICER   |
| Current HepB vaccination coverage (14%) | 28.54 | 29.99 | – | – | – |
| Expanding HepB vaccination coverage (80%) | 28.62 | 28.67 | 0.08 | USD-1.32 | – 16.5 |

ICER Incremental cost-effectiveness ratio, USD United States Dollar
Fig. 2 Cost-effectiveness analysis of increasing hepatitis B vaccination coverage.

ICER: incremental cost-effectiveness ratio; P_dieSeq: probability of die due to sequelae; P_dieinf: probability of die due to Hepatitis B virus infection; P_CronHBV: probability of chronic hepatitis B virus progression; P_untreatseq: probability of untreated HCWs with sequelae; C_labinv: cost of lab investigation; C_hosp: cost of hospitalization; P_treatchrohepa: probability of treated HCWs with chronic hepatitis; C_txt: cost of CHB treatment with tenofovir and optionally with diuretics as a prophylaxis for sequelae; P_dieoth: probability of die due to other causes; P_infectunvacc: probability of infection in unvaccinated HCWs; P_current: probability of current vaccine coverage; E_vacc: effectiveness of Vaccine; P_immun: probability of developing immunity; P_Sucsep: probability of susceptibility; P_sequelae: probability of progressing to sequelae; P_deathacuhep: probability of death due to acute hepatitis.

Fig. 3 Tornado diagram of current hepatitis coverage vs increasing current hepatitis coverage.
Discussion
The foremost aim of this economic evaluation was to compare the cost-effectiveness analysis of increasing vaccination by 80% vs non-mandatory current coverage (14%). The costs per healthcare worker and the benefit in health in terms of LY gains were calculated. This analysis used a variety of secondary data, primarily effectiveness data, that were taken from published articles. In addition, TASH was used to gather estimated cost data for CHB treatment and vaccination [1, 6, 25]. For every LY gained over a lifetime horizon, the new expanded coverage (80%) strategy costs USD 16.5 less than the coverage by the current vaccination (14%) strategy. Therefore, increasing vaccination coverage is essential, since it is a less expensive and highly effective strategy to combat HepB infection in healthcare personnel. Deterministic sensitivity analyses showed that varying the probability of different variables of cost and effectiveness as the new strategy significantly dominates the current program (Fig. 2). While tornado result indicates that some variables impact the ICER value (Fig. 3). The Cost-effectiveness threshold of USD 2,349, which was three times Ethiopia’s GDP, was used to check the affordability of the new strategy. Therefore, since the ICER is negative, implementing the new expanding strategy may have more advantages and be more cost-effective for FMOH to vaccinate its HCWs.

In general, increasing vaccination rates among HCWs to 80% from the current coverage (14%) was found to be more cost-effective in Ethiopia. Thus, the HepB monovalent vaccine offers HCWs lifetime protection with a 90% effectiveness rate in preventing infection [18]. However, the slight reduction of the prevalence (from 7.4% to 6%) from 2016 to 2019 among HCWs in Ethiopia may be associated with lower vaccination coverage through the current non-mandatory strategy [15]. Therefore, the new strategy (expanding to 80%) is highly suggested in Ethiopia, because it was more effective and saves the additional costs that the current coverage (14%) strategy would have required. For example, adopting a mandatory vaccination strategy could be a strategy to increase coverage. A mandatory vaccination strategy was adopted in several nations, including Australia, Austria, Belgium, Canada, the Czech Republic, Germany, Greece, Holland, Ireland, Italy, Poland, Slovakia, Sweden, and the United States, and they also reported that it was effective in lowering the rate of HBV infection among HCWs [26–28]. Economic evaluations are not a common practice in Ethiopia’s healthcare system, so conducting such an analysis would help decision-makers and public healthcare payers in allocating their limited healthcare resources cost-effectively. Therefore, public policy makers such as Ethiopian FMOH recommended adopting and applying the expanded HepB vaccination strategy for HCWs across the country.
Study limitation
This economic analysis has some limitations, particularly concerning costing variables. We did not include viral transmission rates among study participants due to a lack of country-specific data, which might have underestimated the benefit of our findings. Indirect costs related to increasing vaccination coverage, such as vaccine transport and cold chain equipment cost, were not included. Even though the expansion of vaccination coverage across the country’s healthcare facilities requires a high investment of capital items. Therefore, we recommend for future studies include those costs. On the other hand, the cost of acute HepB treatment and the cost of a liver transplant for patients with liver failure were not explicitly determined or included. Direct non-medical costs such as transportation costs and lost wages resulting from illness for every member of the healthcare workforce were also excluded. Although this study places a lot of emphasis on the need to reduce occupational exposure to HepB infection in HCWs by providing vaccines, it does not estimate the cost of screening before vaccination and it makes the methodological supposition that all HCWs are susceptible and eligible for vaccination. Despite all these limitations, efforts have been made to use reliable data by gathering cost data from practicing physicians and other healthcare professionals in TASH. A sensitivity analysis was also performed to test the model’s robustness and determine whether it is consistent with the base-case analysis or not.

Conclusions
From this economic evaluation, it is possible to conclude that increasing current vaccine coverage from 14% to at least 80% among all Ethiopian healthcare workforce was the most cost-effective strategy. As long as expanding hepatitis B vaccine coverage does not incur additional costs and in the meantime, it improves the healthy life of susceptible HCWs and Ethiopian FMOH should work on its implementation.

Abbreviations
ALT: Alanine amino transferase; AST: Aspartate amino transferase; BIR: Bilirubin; BUN: Blood urea nitrogen; CHB: Chronic hepatitis B; DNA: Deoxyribo-nucleic acid; ELY: Expected life year; EPSA: Ethiopian pharmaceutical supply agency; HCW: Healthcare worker; HepB: Hepatitis B; INR: International normalized ratio; Lys: Life years; QALY: Quality adjusted life year; TASH: Tikur Anbesa Specialized Hospital; USD: United States Dollar, USA: United States of America, WHO: World Health Organization.

Acknowledgements
We would like to thank Tikur Anbesa Specialized Hospital (TASH) for their fantastic collaboration to provide cost-related data.

Author contributions
DT and GA conceived the research problem and collected the data set. DT, GA, and WA did a literature review. DT and GA performed data analysis, and GA was a major contributor in writing the manuscript. The manuscript has been read and approved by all authors in this study.

Funding
None.

Declarations

Ethics approval and consent to participate
“No applicable”, because this was a retrospective study that used secondary and published data. We only gathered related cost data for vaccination and chronic hepatitis B treatment after an oral discussion about the study objective with TASH.

Consent for publication
“No applicable”.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data generated and analyzed during this study are included in this published article and are publicly available.

Author details
1. Department of Pharmacy, Madda Walabu University, Bale Robe, Ethiopia.
2. Department of Pharmacy, Arba Minch University, Arba Minch, Ethiopia.
3. Department of Pharmaceutics, University of Gondar, Gondar, Ethiopia.

Received: 14 June 2022  Accepted: 3 October 2022
Published online: 17 October 2022

References
1. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011;17(2):87–95.
2. World Health Organization. Combating hepatitis B and C to reach elimination by 2030 [Internet]. World Health Organization. Geneva, Switzerland, 2016. Available from: http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016_04_eng.pdf?ua=1.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.
4. Tsatsilong HOF, Noubiap JN, Nansseu JRN, Aminde LN, Bigna JIR, Ndze VN, et al. Hepatitis B infection awareness, vaccine perceptions and uptake, and serological profile of a group of health care workers in Yaoundé, Cameroon. BMC Public Health. 2016;16(1).
5. World Health Organization. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic Hepatitis B infection. 2015. Geneva: World Health Organisation [Internet]. 2015. 124 p. Available from: http://apps.who.int/iris/bitstream/10665/154500/1/9789241549059_eng.pdf?ua=1&ua=1
6. Chang MS, Nguyen MH. Epidemiology of hepatitis B and the role of vaccination. Best Pract Res Clin Gastroenterol. 2017;31(3):239–47.
7. Béguelin C, Fall F, Seydi M, Wandeler G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Rev Gastroenterol Hepatol. 2018;12(6):537–46.
8. World Health Organization. Position paper on Hepatitis B vaccine [Internet]. Vol. 84. Weekly Epidemiological Record. 2009. p. 405–19. Available from: http://www.who.int/wer.
9. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott J]. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10033):1546–55.
10. Nigussie ZY, Tafere TE, Kassa GT. Managements of exposure to blood and body fluids among healthcare workers and medical students in University of Gondar Hospital, Northwest of Ethiopia. Glob J Med Res Interdiscip. 2013;3(3):1–9.

11. Topuridze M, Butashvili M, Kamkamidze G, Kajaia M, Morse D, McNutt LA. Barriers to hepatitis B vaccine coverage among healthcare workers in the republic of Georgia: an international perspective. Infect Control Hosp Epidemiol. 2010;31(2):158–64.

12. Gebremariam AA, Tsegaye AT, Shiferaw YF, Reta MM, Getaneh A. Sero-prevalence of Hepatitis B Virus and Associated Factors among Health Professionals in University of Gondar Hospital, Northwest Ethiopia. Adv Prev Med. 2019;2019:1–5.

13. Gizachew Tadesse Akalu, Addis Tamire Woldemariam, Abate Bane Shewaye DAG, Abebe Habteselasie Demise, Melaku Tesfaye Debele KDT. Burden of hepatitis-B infections and risk factors among healthcare workers in resource limited setting, Addis Ababa, Ethiopia. EC Microbiol. 2016;4(2016):722–31.

14. FMOH. Prevention and control National strategy for prevention and control of viral hepatitis Of viral hepatitis. Addis Ababa, Ethiopia, 2016.

15. Yazie TD, Tebeje MG. An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia. BMC Infect Dis. 2019;19(1):917. https://doi.org/10.1186/s12879-019-4486-1.

16. Ayalew MB, Horsa BA. Hepatitis B Vaccination Status among Health Care Workers in a Tertiary Hospital in Ethiopia. 2017;2017.

17. Abege G, Azage M. Hepatitis B vaccine knowledge and vaccination status among health care workers of Bahir Dar City Administration, Northwest Ethiopia: a cross sectional study. BMC Infect Dis. 2015;15(1):30. https://doi.org/10.1186/s12879-015-0756-8.

18. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.

19. World Health Organisation. World Health Organization. Hepatitis B vaccines: WHO position paper—July 2017. Wkly Epidemiol Rec. 2017;27(92):53–76.

20. FDRE (MOH). National Health Workforce Update Development Directorate Bulletin 2nd Edition. In 2019. Available from: http://www.moh.gov.et/ejcc/en/human-resource.

21. Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, Jiles R, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2013;62(10):1–19.

22. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20(4):607–28.

23. AbrhamBongasse L, TekeseteTesfazig M, GigarAbera G, Adrado Angelo T, LakevBelayneh K, Andrey L, et al. Evaluating constraints and prospects in public health supply Chain: The Case of the Ethiopian Pharmaceutical Supply Agency (EPSA). Acta Sci Pharm Sci. 2020;4(2):01–3.

24. PFSA. Pharmaceuticals procurement list [Internet]. 2018. p. 1–80. Available from: www.pfsa.gov.et Accessed 12 Dec 2018.

25. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis B immunization for US college students. J Am Coll Health Assoc. 2003;51(6):227–36.

26. Smithers P, Murray SB, Stewart S, Skull S. Hospital health care worker (HCW) vaccination coverage after implementation of an HCW vaccination policy, Aust Health Rev. 2003;26(1):76–83.

27. Wang J. Strategy of hepatitis B vaccination among medical staff in different epidemic regions in the world, China. Contin Med Educ. 2016;8(31):227–9.

28. De Schryver A, Claesen B, Meheus A, Van Sprundel M, Francois G. European survey of Hepatitis B vaccination policies for healthcare workers. Eur J Public Health. 2011;21(3):338–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.